AKT is modified by SUMO at K276 and K301 within its kinase domain, and its mutation (Akt E17 K) increases its SUMOylation levels in several human cancer types, enhancing its capacity to regulate fibronectin and Bcl-x alternative splicing patterns (Risso et al., 2013). This evidence concerns the gene AKT1 and cancer.